QuidelOrtho Corp director Kenneth J. Widder reported an equity award tied to restricted stock units. On May 29, 2026, 6,829 restricted stock units vested and were converted into 6,829 shares of common stock at no cash cost, reflecting a compensation-related grant rather than a market purchase.
Following these transactions, Widder directly holds 43,890 shares of QuidelOrtho common stock. The filing shows an exercise of the corresponding derivative position, leaving no remaining restricted stock units from this grant.
QuidelOrtho Corp director Mary Lake Polan, Ph.D., reported routine equity compensation activity involving restricted stock units and common shares. On May 29, 2026, 6,829 restricted stock units vested and were converted into 6,829 shares of common stock at a conversion price of $0.00 per share. These units had been previously reported and each unit represented the right to receive one share of QuidelOrtho common stock. Following the conversion, she held 19,469 shares of common stock directly, while a separate 17,353 shares of common stock were reported as held indirectly through an LLC.
QuidelOrtho Corp director Kenneth F. Buechler reported a compensation-related stock award and vesting of restricted stock units. On May 29, 2026, 6,829 restricted stock units vested and were converted into 6,829 shares of common stock at no exercise price. This is reflected as a grant/acquisition of common shares and an exercise of the corresponding restricted stock unit derivative, leaving no units from that grant outstanding. Following these transactions, Buechler directly holds 108,750 shares of QuidelOrtho common stock.
QuidelOrtho Corp director John R. Chiminski reported routine equity compensation activity. On May 29, 2026, restricted stock units vested and were converted into 6,829 shares of Common Stock, reflecting a previously reported award.
Each restricted stock unit represented one share of QuidelOrtho common stock, and the units vested on May 29, 2026. After this grant and corresponding RSU release, Chiminski directly holds 9,352 shares of QuidelOrtho Common Stock, with no remaining position reported in the related RSUs.
QuidelOrtho Corp director R. Scott Huennekens reported a routine equity compensation event. He acquired 6,829 shares of common stock at a stated price of $0.0000 per share through the release of previously granted restricted stock units. These restricted stock units vested on May 29, 2026 and each unit converted into one share of common stock. Following this vesting and conversion, he directly holds 9,352 shares of QuidelOrtho common stock. The filing shows no open-market purchases or sales, only the vesting and exercise of an equity award.
QuidelOrtho Corp director Joseph D. Wilkins Jr. reported equity compensation activity involving 6,829 shares. He received 6,829 shares of common stock on May 29, 2026 through the release of previously granted restricted stock units, with no sales reported. Following these transactions, he directly owns 18,705 shares of QuidelOrtho common stock. The filing also shows the corresponding exercise of 6,829 restricted stock units into common shares, with no remaining units from this grant after vesting.
QuidelOrtho Corp director Ann D. Rhoads reported equity compensation activity involving restricted stock units. She received 6,829 shares of Common Stock at no cost, related to previously reported restricted stock units. These restricted stock units, each representing one share of common stock, vested on May 29, 2026 and were exercised into common shares the same day. Following these transactions, she holds 23,257 shares of QuidelOrtho common stock directly, with no remaining position in the exercised restricted stock units.
QuidelOrtho Corp director Michael Edward L. received 6,829 shares of Common Stock as a stock award on May 29, 2026, when previously granted restricted stock units vested. These RSUs were exercised into Common Stock, bringing his direct holdings to 28,181 shares, with no open-market buying or selling.
QuidelOrtho Corp director Evelyn S. Dilsaver reported an equity award and related vesting of restricted stock units. On May 29, 2026, she acquired 6,829 shares of common stock at no cost through the release of previously reported restricted stock units. Each unit converted into one share of common stock when the units vested on May 29, 2026. Following these transactions, she directly holds 17,453 shares of QuidelOrtho common stock, and the reported restricted stock unit grant has been fully exercised.
QuidelOrtho Corp director Ann D. Rhoads reported routine equity compensation activity. She received a total of 1,407 shares of common stock on May 22, 2026 through the release of previously reported restricted stock units.
Footnotes state these restricted stock units each convert into one share of common stock and that their release was deferred under QuidelOrtho’s deferred compensation program for participating non-employee directors, occurring according to her elected deferral schedule. The filing shows no open‑market purchases or sales, only grants and conversions of equity awards.